Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

153.59 -0.44 (-0.29%)
Streaming Delayed Price Updated: 12:03 PM EDT, Apr 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
News headline image
Cullen Sells 1.4 Million Dow Shares Worth $39.7 Million Amid Steep Stock Decline ↗
Via The Motley Fool
Topics Stocks
News headline image
Pharma's Direct-To-Patient Wave Hits Novartis Next ↗
The Pharmaceutical Research and Manufacturers of America (PhRMA) outlined initiatives to bolster U.S. manufacturing, ease patient costs, and improve access to medicine. 
Via Benzinga
News headline image
Digital Pharma Advances 2026: AI and Patient-Centric Strategies Transform Pharma Marketing
Via PRLog
Topics Artificial Intelligence
News headline image
AstraZeneca's Strategic Listing Harmonization: A Unified Global Platform for Growth
AstraZeneca (LSE: AZN, NASDAQ: AZN) has announced a significant strategic move to harmonize its stock market listings across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York... 
Via MarketMinute
Topics Economy
Monte Rosa Therapeutics Stock Scores Biggest Gain In Nearly A Year On $5.7B Novartis Deal For Immune-Mediated Diseases ↗
Via Stocktwits
Google DeepMind Chief Eyes Radical AI-Powered Shift In Drug Discovery Speed — Eli Lilly, Novartis Are Already Onboard ↗
Via Stocktwits
Why Is Avidity Biosciences Stock Down 20% Pre-market Today? ↗
Via Stocktwits
News headline image
Novartis AG-Sponsored ADR (NYSE:NVS): A Strong Dividend Stock with High Profitability and Sound Financial Health ↗
Novartis (NVS) offers a strong 3.58% dividend yield with a history of steady payments, supported by high profitability and sound financial health for sustainable income. 
Via Chartmill
News headline image
Major Insider Sale Casts Shadow on LENZ Therapeutics' Valuation
San Diego, CA – September 27, 2025 – LENZ Therapeutics (NASDAQ: LENZ) is facing heightened scrutiny this week following a significant insider share sale by a major shareholder, Versant Venture Capital... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Pharma Tariffs Back In Spotlight On New Trump Threat ↗
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
News headline image
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
News headline image
Trump's New Tariff Barrage Targets Drugs, Trucks, Cabinets: President Says Move Will Protect Manufacturers From 'Unfair Outside Competition' ↗
President Donald Trump announced a barrage of new tariffs on Thursday, aimed at pharmaceuticals, heavy trucks and home furnishings in particular, to shore up domestic industry in these sectors, and... 
Via Benzinga
Topics Government World Trade
News headline image
Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move? ↗
Eli Lilly and Company (NYSE: LLY) shares are trading lower after the company ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it... 
Via Benzinga
News headline image
AI Takes Center Stage in Biodefense: DARPA's NODES Program Promises to Revolutionize Pandemic and Biowarfare Protection
In a groundbreaking leap for global health security, the Defense Advanced Research Projects Agency (DARPA) officially launched its Network of Optimal Dynamic Energy Signatures (NODES) program in July... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch ↗
On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. 
Via Benzinga
News headline image
Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies ↗
A judge upholds Maine's contract pharmacy law, rejecting drugmakers' claims that it conflicts with federal rules governing the 340B drug discount program. 
Via Benzinga
News headline image
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection ↗
FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with Germany as the launch market. 
Via Benzinga
News headline image
Roche Targets Top Spot In Weight Loss Drug Market ↗
Roche advances weight loss drug CT-388 to Phase III, boosts pipeline with major acquisitions. 
Via Benzinga
News headline image
Novartis Builds US Drug Reserves Against Potential Tariffs ↗
Novartis bolsters U.S. drug reserves and plans $23 billion in investments as CEO Vas Narasimhan addresses tariff risks and trade policy uncertainty. 
Via Benzinga
Topics World Trade
News headline image
Lilly's AI Gambit: TuneLab Poised to Reshape Biotech Drug Discovery Landscape
Eli Lilly and Company (NYSE: LLY) has unveiled its groundbreaking TuneLab Platform, an artificial intelligence (AI) and machine learning (ML) initiative designed to democratize advanced drug discovery... 
Via MarketMinute
Topics Animal Testing Artificial Intelligence Intellectual Property
News headline image
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca... 
Via MarketMinute
News headline image
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments ↗
Monte Rosa's stock jumps as it partners with Novartis to develop degraders for immune diseases, with up to $5.7 billion in payments. 
Via Benzinga
News headline image
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Value Investors ↗
Discover Novartis (NVS), an undervalued pharma stock with strong fundamentals, high profitability, and a solid margin of safety for value investors. 
Via Chartmill
News headline image
This Applied Materials Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
Wall Street Cheers Nebius-Microsoft Megadeal While Apple Misses the Mark ↗
U.S. markets closed higher on Tuesday, buoyed by fresh labor data signaling a cooling job market—potentially paving the way for Fed rate cuts. Nebius soared nearly 50% on a multibillion-dollar AI-cloud... 
Via Chartmill
Topics Economy
News headline image
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz ↗
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential... 
Via Benzinga
Topics ETFs Government
News headline image
Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense' ↗
Novartis agreed to buy a cardiovascular-focused biotech company 
Via Investor's Business Daily
News headline image
Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion ↗
Tourmaline Bio shares skyrocketed Tuesday after Novartis agreed to buy the cardiovascular-focused biotech company. 
Via Investor's Business Daily
News headline image
Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver ↗
Novartis is betting big on radioligand cancer therapy, but while the long-term growth story looks strong, NVS stock may face a short-term pullback 
Via MarketBeat
News headline image
Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition ↗
Novartis agreed to acquire Tourmaline Bio for $1.4 billion as pacibekitug shows strong trial results for inflammation and cardiovascular risk reduction. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.